Zoster Vaccine Session: Introduction

ACIP Meeting
October 29, 2020

Grace Lee, MD, MPH
ACIP Chair, Herpes Zoster Work Group
## 2020 Herpes Zoster Work Group

### ACIP Members
- Grace Lee, MD, MPH (Chair)
- Lynn Bahta, RN, MPH

### Ex Officio Members
- Paula Agger, MD, MPH (FDA)
- Jeffrey Cohen, MD (NIH)
- Darcie Everett, MD, MPH (FDA)
- Jeffrey Kelman, MD (CMS)

### Liaison Representatives
- Jeffrey Duchin, MD (IDSA/NACCHO)
- Mary Pat Friedlander, MD (AAFP)
- Sandra Fryhofer, MD (ACP/AMA)
- Elizabeth Rausch-Phung, MD, MPH (AIM)
- William Schaffner, MD (NFID)
- Kenneth Schmader, MD (AGS)
- Adam Welch, PharmD (APhA)

### Invited Consultants
- Robin Avery, MD
- Edward Belongia, MD
- Al Benson, MD
- Paul Cieslak, MD
- Jeffrey Curtis, MD, MPH
- Jay Fishman, MD
- Rafael Harpaz, MD, MPH
- Camille Kotton, MD
- Kelly Moore, MD, MPH
- Vicki Morrison, MD
- Steven Pergam, MD
- Lisa Prosser, PhD

### CDC Lead
- Tara Anderson, DVM, MPH, PhD
In October 2017, the ACIP made the following recommendations:

1) Recombinant zoster vaccine (RZV, Shingrix) is recommended for the prevention of herpes zoster and related complications for immunocompetent adults aged ≥50 years.

2) RZV is recommended for the prevention of herpes zoster and related complications for immunocompetent adults who previously received zoster vaccine live (ZVL, Zostavax).

3) RZV is preferred over ZVL for the prevention of herpes zoster and related complications.

CDC 2018 Herpes Zoster Policy Note recommendations serve as a supplement to the existing recommendations for the use of ZVL in immunocompetent adults aged ≥60 years.

Dooling et al. MMWR Jan 25, 2018
Herpes Zoster Vaccine Updates

- **ZVL (Zostavax)**
  - Effective July 1, 2020, Zostavax no longer sold in the United States
  - Remaining product will expire by November 18, 2020

- **RZV (Shingrix)**
  - 33 million doses distributed from launch through second quarter of 2020
  - Shingrix inventory available to meet demand across all distribution channels
  - European Commission approved an expanded indication on August 25, 2020; Shingrix now approved in the European Union for prevention of herpes zoster and postherpetic neuralgia in adults 50 years of age or older, and adults 18 years of age or older at increased risk of herpes zoster
  
Figure: Weekly Uptake Rate of RZV among Medicare Beneficiaries ≥65 — CMS Medicare Enrollment and Claims Data, United States, January 6, 2019 – July 20, 2019 and January 5, 2020 – July 18, 2020

- First Confirmed Case in the U.S. (1/20)
- National Emergency Declared (3/13)

Weekly Uptake Rate, 2019
Weekly Uptake Rate, 2020

CDC, unpublished data
Herpes Zoster Work Group Activities since June 2019

- June 2019 ACIP Meeting Presentations
  - Summary of RZV post-licensure safety monitoring activities to date in three systems: Vaccine Adverse Event Reporting System (VAERS), Vaccine Safety Datalink (VSD), Medicare data
  - Summary of Herpes Zoster Work Group (HZWG) interpretation of findings

- 14 Subsequent HZWG Meetings
  - RZV post-licensure safety and uptake monitoring
  - RZV efficacy and immunogenicity in immunocompetent and immunocompromised adults
  - PICO for use of RZV in immunocompromised adults
RZV Safety Monitoring Updates and Next Steps

- Update on post-licensure safety monitoring of RZV in VAERS
- VSD update on post-licensure safety monitoring of RZV
- Risk of Guillain-Barré syndrome following herpes zoster
- Summary and planned risk-benefit analysis regarding use of RZV in immunocompetent adults
Acknowledgments

- **ACIP HZWG**: Paula Agger, Robin Avery, Lynn Bahta, Edward Belongia, Al Benson, Paul Cieslak, Jeff Cohen, Jeff Curtis, Jeff Duchin, Darcie Everett, Jay Fishman, Mary Pat Friedlander, Sandra Fryhofer, Rafael Harpaz, Jeff Kelman, Camille Kotton, Vicki Morrison, Kelly Moore, Steve Pergam, Lisa Prosser, Elizabeth Rausch-Phung, Bill Schaffner, Ken Schmader, Adam Welch

- **HZWG CDC Lead**: Tara Anderson